Skip to Content

Genenta presents preliminary clinical data from a Phase 1/2 study in patients with glioblastoma multiforme at international scientific meetings in Europe and the USA. Genenta will attend the American Society of Hematology Conference in Orlando (USA)

Dec 04, 2019

MILANO (Italy) / NEW YORK (NY, USA) — Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem cell gene therapy for cancer (Temferon™), announced that they presented preliminary clinical data from the TEM-GBM_001 clinical trial at the following international scientific meetings:

  • European Association of Neuro-Oncology (EANO) in Lyon (France), September 19-22, 2019
  • European Society Gene & Cell Therapy (ESGT) in Barcelona (Spain), October 22-25, 2019
  • Association Italian of Neuro-Oncology in Udine (Italy), November 10-12, 2019
  • Society Neuro Oncology (SNO) in Phoenix (USA), November 20-24, 2019

Dr Bernhard Gentner, Co-Founder of Genenta, will also present relevant data for the TEM-MM-101 study at a poster session at the American Society of Hematology Conference (ASH) in Orlando (Arizona, USA) between 7th-10th of December, 2019.